Tafamidis for transthyretin amyloidosis.

Abstract

Tafamidis meglumine (Vyndaqel®, Pfizer) is a novel, first-in-class drug for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP), a rare neurodegenerative disorder characterized by progressive sensory, motor and autonomic impairment that is ultimately fatal. Pathogenic mutations in the transthyretin (TTR) protein lead to destabilization of its tetrameric structure and subsequent formation of amyloid aggregates. Tafamidis is a small-molecule inhibitor that binds selectively to TTR in human plasma and kinetically stabilizes the tetrameric structure of both wild-type TTR and a number of different mutants. Clinical trials indicate that tafamidis slows disease progression in patients with TTR-FAP and reduces the burden of disease, demonstrating improvement in small and large nerve fiber function, modified body mass index and lower extremity neurological examination. Tafamidis has been granted marketing authorization by the European Commission for the treatment of TTR-FAP and the U.S. Food and Drug Administration is currently reviewing this drug for the same indication.

• Authors: J de Lartigue
• Journal: Drugs of today (Barcelona, Spain : 1998) (Drugs Today (Barc)) Vol. 48 Issue 5 Pg. 331-7 (May 2012) ISSN: 1699-3993 [Print] Spain
• PMID: 22645721 (Publication Type: Journal Article, Review)
• Copyright: Copyright 2012 Prous Science, S.A.U. or its licensors. All rights reserved.

Chemical References

• Benzoxazoles
• Neuroprotective Agents
• Prealbumin
• tafamidis

Topics

• Amyloid Neuropathies, Familial (drug therapy, metabolism, physiopathology)
• Animals
• Benzoxazoles (adverse effects, pharmacology, therapeutic use)
• Genotype
• Humans
• Mutation
• Neuroprotective Agents (adverse effects, pharmacology, therapeutic use)
• Prealbumin (chemistry, drug effects, genetics, metabolism)
• Randomized Controlled Trials as Topic